Fig. 6

FAP-targeted CAR-T cells eliminate CAFs and change tumor microenvironment in vivo. C57BL/6 mice were injected s.c. with PANC02-A2 or KPC1199 cells and treated with CAR-T cells after the tumor was established. To exclude the influence of tumor volume difference by distinct CAR-T cells, tumor tissue was harvested 7 days after treatment. a–c Analysis of the CAFs in tumor tissues of PANC02-A2 and KPC1199 allografts. a The representative images of CAFs immunostained with α-SMA in tumor tissues from each treatment group. b q-PCR measured the mRNA expression of CXCL12 in tumor tissues from each treatment group. c PET image labeling FAP by FAPI in PANC02-A2 allografts 7 days after the treatment of FAP-mBBZ or UTD T cells.  d–f  Analysis of the immune cell in tumor tissues of PANC02-A2 allografts. d The representative flow cytometry plots showing the frequencies of tumor-infiltrating CD8⁺ and CD4⁺ cells in CD3⁺ T of each treatment group. e The representative flow cytometry plots showing the frequencies of tumor-infiltrating CD45⁺ immune cells and MDSCs of each treatment group. f Flow cytometry quantitation of tumor-infiltrating immune cells of each treatment group. g–i Analysis of the immune cell in tumor tissues of KPC1199 allografts. g The representative flow cytometry plots showing the frequencies of tumor-infiltrating CD8⁺ and CD4⁺ cells in CD3⁺ T of each treatment group. h The representative flow cytometry plots showing the frequencies of tumor-infiltrating CD45⁺ immune cells and MDSCs of each treatment group. i Flow cytometry quantitation of tumor-infiltrating immune cells of each treatment group. The images were obtained under original magnification 200×. Scale bars, 100 μm. All data are presented as the mean ± SEM of triplicate experiments. *p < 0.05, **p < 0.01, *** p < 0.001